SI1562577T1 - Acetyl-L-karnitin za preprečevanje in/ali zdravljenje perifernih nevropatij, induciranih s talidomidom - Google Patents
Acetyl-L-karnitin za preprečevanje in/ali zdravljenje perifernih nevropatij, induciranih s talidomidomInfo
- Publication number
- SI1562577T1 SI1562577T1 SI200332090T SI200332090T SI1562577T1 SI 1562577 T1 SI1562577 T1 SI 1562577T1 SI 200332090 T SI200332090 T SI 200332090T SI 200332090 T SI200332090 T SI 200332090T SI 1562577 T1 SI1562577 T1 SI 1562577T1
- Authority
- SI
- Slovenia
- Prior art keywords
- thalidomide
- carnitine
- acetyl
- prevention
- treatment
- Prior art date
Links
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 title 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title 1
- 208000027232 peripheral nervous system disease Diseases 0.000 title 1
- 208000033808 peripheral neuropathy Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229960003433 thalidomide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/292,823 US20030199535A1 (en) | 1998-07-30 | 2002-11-13 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| EP03775788A EP1562577B1 (en) | 2002-11-13 | 2003-10-23 | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by thalidomide |
| PCT/IT2003/000656 WO2004043454A1 (en) | 2002-11-13 | 2003-10-23 | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1562577T1 true SI1562577T1 (sl) | 2012-01-31 |
Family
ID=32312146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200332090T SI1562577T1 (sl) | 2002-11-13 | 2003-10-23 | Acetyl-L-karnitin za preprečevanje in/ali zdravljenje perifernih nevropatij, induciranih s talidomidom |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030199535A1 (enExample) |
| EP (1) | EP1562577B1 (enExample) |
| JP (1) | JP2006508958A (enExample) |
| KR (1) | KR20050075012A (enExample) |
| CN (1) | CN1708297A (enExample) |
| AR (1) | AR041947A1 (enExample) |
| AT (1) | ATE526958T1 (enExample) |
| AU (2) | AU2003283807B2 (enExample) |
| BR (1) | BR0316131A (enExample) |
| CA (1) | CA2505937C (enExample) |
| CY (1) | CY1112399T1 (enExample) |
| DK (1) | DK1562577T3 (enExample) |
| ES (1) | ES2374503T3 (enExample) |
| MX (1) | MXPA05004752A (enExample) |
| PL (1) | PL379244A1 (enExample) |
| PT (1) | PT1562577E (enExample) |
| SI (1) | SI1562577T1 (enExample) |
| TW (1) | TWI362260B (enExample) |
| WO (1) | WO2004043454A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018767A2 (en) * | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| ITMI20070817A1 (it) * | 2007-04-19 | 2008-10-20 | Farmacetika Ltd | Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi |
| JP4208036B1 (ja) * | 2007-04-26 | 2009-01-14 | 日本新薬株式会社 | 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 |
| WO2009028605A1 (ja) * | 2007-08-31 | 2009-03-05 | Kyushu University, National University Corporation | 抗がん剤による末梢神経障害の予防又は軽減剤 |
| AU2008348717B2 (en) * | 2007-10-30 | 2013-09-19 | Trophos | Novel composition for treating the side effects of anticancer treatments |
| EA201170732A1 (ru) * | 2008-12-01 | 2011-12-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| ITPZ20130005A1 (it) * | 2013-07-05 | 2015-01-06 | Teodosio Antonio Ferrara | Metabolismo energetico e omeostasi |
| CN110121563A (zh) | 2016-11-09 | 2019-08-13 | 奇根科学有限责任公司 | 在边合成边测序中作为成像试剂的光保护混合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713370A (en) * | 1972-11-06 | 1987-12-15 | Felice Stephen L De | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats |
| US4599352A (en) * | 1984-03-01 | 1986-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic platinum (IV) complexes and compositions |
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| DE69923322T2 (de) * | 1998-07-30 | 2005-12-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung |
-
2002
- 2002-11-13 US US10/292,823 patent/US20030199535A1/en not_active Abandoned
-
2003
- 2003-10-23 PT PT03775788T patent/PT1562577E/pt unknown
- 2003-10-23 KR KR1020057008678A patent/KR20050075012A/ko not_active Ceased
- 2003-10-23 ES ES03775788T patent/ES2374503T3/es not_active Expired - Lifetime
- 2003-10-23 WO PCT/IT2003/000656 patent/WO2004043454A1/en not_active Ceased
- 2003-10-23 AU AU2003283807A patent/AU2003283807B2/en not_active Ceased
- 2003-10-23 CA CA2505937A patent/CA2505937C/en not_active Expired - Fee Related
- 2003-10-23 BR BR0316131-5A patent/BR0316131A/pt not_active IP Right Cessation
- 2003-10-23 CN CNA2003801022169A patent/CN1708297A/zh active Pending
- 2003-10-23 JP JP2004551161A patent/JP2006508958A/ja active Pending
- 2003-10-23 PL PL379244A patent/PL379244A1/pl unknown
- 2003-10-23 SI SI200332090T patent/SI1562577T1/sl unknown
- 2003-10-23 EP EP03775788A patent/EP1562577B1/en not_active Expired - Lifetime
- 2003-10-23 DK DK03775788.7T patent/DK1562577T3/da active
- 2003-10-23 MX MXPA05004752A patent/MXPA05004752A/es active IP Right Grant
- 2003-10-23 AT AT03775788T patent/ATE526958T1/de active
- 2003-10-30 TW TW092130286A patent/TWI362260B/zh not_active IP Right Cessation
- 2003-11-12 AR ARP030104151A patent/AR041947A1/es not_active Application Discontinuation
-
2006
- 2006-04-13 US US11/402,961 patent/US20060183798A1/en not_active Abandoned
-
2009
- 2009-04-08 AU AU2009201384A patent/AU2009201384A1/en not_active Abandoned
-
2012
- 2012-01-03 CY CY20121100001T patent/CY1112399T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003283807A1 (en) | 2004-06-03 |
| PT1562577E (pt) | 2012-01-12 |
| EP1562577B1 (en) | 2011-10-05 |
| ES2374503T3 (es) | 2012-02-17 |
| CY1112399T1 (el) | 2015-12-09 |
| BR0316131A (pt) | 2005-09-27 |
| US20060183798A1 (en) | 2006-08-17 |
| US20030199535A1 (en) | 2003-10-23 |
| TW200410683A (en) | 2004-07-01 |
| JP2006508958A (ja) | 2006-03-16 |
| PL379244A1 (pl) | 2006-08-07 |
| CN1708297A (zh) | 2005-12-14 |
| AR041947A1 (es) | 2005-06-01 |
| AU2003283807B2 (en) | 2009-12-03 |
| TWI362260B (en) | 2012-04-21 |
| ATE526958T1 (de) | 2011-10-15 |
| KR20050075012A (ko) | 2005-07-19 |
| WO2004043454A1 (en) | 2004-05-27 |
| AU2009201384A1 (en) | 2009-05-07 |
| CA2505937A1 (en) | 2004-05-27 |
| MXPA05004752A (es) | 2005-08-02 |
| EP1562577A1 (en) | 2005-08-17 |
| CA2505937C (en) | 2011-07-26 |
| DK1562577T3 (da) | 2012-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
| TWI347188B (en) | Treatment and prevention of osteoporosis | |
| EP1617805A4 (en) | METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS | |
| SI1487541T1 (sl) | Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja | |
| PL377344A1 (pl) | Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia | |
| AU2003297356A8 (en) | Prevention and treatment of cardiac arrhythmias | |
| GB2418025B (en) | Device for the prevention or treatment of ulcers | |
| IL158181A0 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| AP2005003336A0 (en) | Combination for the treatment of ADHD | |
| AU2003263760A1 (en) | Methods for the treatment or prevention of obesity | |
| PL379244A1 (pl) | Acetylo L-karnityna do zapobiegania i/lub leczenia neuropatii obwodowej indukowanej przez środki przeciwrakowe | |
| NO20054913D0 (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
| AU2002364171A8 (en) | Materials and methods for the treatment or prevention of obesity | |
| AU2003251875A8 (en) | Combination therapy for the treatment of neoplasms | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
| IL178903A0 (en) | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions | |
| IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
| AU2003219880A8 (en) | Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease | |
| ZA200605059B (en) | Apparatus for the treatment of wood or wood products | |
| HUP0300990D0 (en) | Synergistic combination for the prophylaxis and treatment of diabetes | |
| ZA200606268B (en) | Treatment of coronary or peripheral ischemia | |
| GB2388027B (en) | Use of palatinose for the treatment of mental stress | |
| EP1671648A4 (en) | PREVENTION AND TREATMENT OF GVHD | |
| GB0221712D0 (en) | Methods of treatment |